31/08/2025
Selamat Hari Merdeka Malaysia!
This year’s National Day marks a meaningful milestone for MYOS. In conjunction with celebrating Malaysia’s 68th Independence Day, MYOS had the privilege of serving as an Educational Partner for a landmark event.
As a professional society still under three years old, we were honored to be invited to chair one of the sessions at the official launch of Tirzepatide in Malaysia. Tirzepatide is a dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist for obesity management, proven to deliver unprecedented results in weight reduction and improvement of obesity-related comorbidities. First approved in 2022 for type 2 diabetes and in 2023 for obesity, it has now reached our shores in August 2025—a timely arrival as Malaysia grapples with a burgeoning epidemic of obesity and diabetes.
MYOS strongly supports the evidence-based, appropriate use of obesity management medications (OMMs). In her Welcome Note, our President, Professor Dr Rohana Abdul Ghani, emphasized that obesity is increasingly recognized as a chronic disease at the forefront of metabolic disorders—on par with diabetes, hypertension, and dyslipidemia. Obesity is not a personal failure of the individual, it is a chronic noncommunicable disease with distinct signs and symptoms, which require specific treatments. The advent of effective OMMs is a beacon of hope in our collective fight against the obesity epidemic.
We look forward to a brighter future for Obesity Medicine in Malaysia, and warmly welcome healthcare and allied health professionals to join us in making obesity treatment more accessible to all who need it.
